Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: Results of a randomized open-label trial

Urology

Volumn 64, Issue 6, 2004, Pages 1177-1181

  Zinner, Norman R ^a,e   Bidair, Mohamed ^b   Centeno, Arthur ^c   Tomera, Kevin ^d  

^a Western Clinical ResearchInc   (United States)

^b La Mesa   (United States)

^c Urology San Antonio   (United States)

^d Alaska Clinical Research Center   (United States)

^e Doctors Urology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOSERELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER HORMONE THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DYSURIA; HEADACHE; HORMONE DETERMINATION; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NOCTURIA; PAIN; PELVIS PAIN SYNDROME; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN TUMOR; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; GOSERELIN; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 10644289275     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.07.033     Document Type: Article

References (15)

1. A.V. Kaisary, C.J. Tyrrell, W.B. Peeling Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma Br J Urol 67 1991 502 508
2. Zoladex Prostate Study Group N.J. Vogelzang, G.W. Chodak, M.S. Soloway Goserelin versus orchiectomy in the treatment of advanced prostate cancer final results of a randomized trial Urology 46 1995 220 226
3. EORTC GU Group and EORTC Data Center L.J. Denis, J.L. Carnelro de Moura, A. Bono Goserelin acetate and flutamide versus bilateral orchiectomy a phase III EORTC trial (30853) Urology 42 1993 119 129
4. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) a phase III randomised trial Lancet 360 2002 103 108
5. M.V. Pilepich, K. Winter, C.A. Lawton Phase III trial of androgen suppression adjuvant to definitive radiotherapy long term results of RTOG study 85-31 (abstract) Proc Am Soc Clin Oncol 22 2003 381
6. E.M. Messing, J. Manola, M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
7. R. St-Arnaud, R. Lachance, A. Dupont Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate Clin Invest Med 9 1986 215 221
8. F. Labrie, A. Dupont, A. Belanger Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer Proc Natl Acad Sci USA 81 1984 3861 3863
9. F. Labrie, A. Dupont, A. Belanger Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist J Urol 138 1987 804 806
10. G.A. Dijkman, F.M. Debruyne, P. Fernandez del Moral A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer Eur Urol 27 1995 43 46
11. A. O'Brien, M. Hibberd Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer J Int Med Res 18 suppl 1 1990 57 68
12. M.F. Sarosdy, P.F. Schellhammer, M.S. Soloway Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer BJU Int 83 1999 801 806
13. R. Sharifi, R.C. Bruskewitz, M.C. Gittleman Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer Clin Ther 18 1996 647 657
14. Dutch South East Cooperative Urological Group P. Fernandez del Moral, G.A. Dijkman, F.M. Debruyne Three-month depot of goserelin acetate clinical efficacy and endocrine profile Urology 48 1996 894 900
15. Leuprolide Study Group R. Sharifi, R. Browneller Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer J Urol 168 2002 1001 1004